NCT06662877 - Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

September 1, 2029

Study Completion Date

September 1, 2029

Conditions

Biliary Tract CancerSecond Line TreatmentChemotherapyTyrosine Kinase Inhibitor

Interventions

DRUG

Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib

Albumin-bound Paclitaxel, 125mg/m2,iv.drip,d1,d8,Q3W +Tegafur Gimeracil Oteracil (S-1) 40-60mg,p.o,bid,d1-d14,Q3W+Anlotinib 10mg,p.o,d1-d14,Q3W

DRUG

Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)

Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W

Trial Locations (1)

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou